

Astellas Pharma Ltd
2000 Hillswood Drive
Chertsey, KT16 0RS

By email to: [REDACTED]

18 February 2016

Dear Dr [REDACTED]

Final Appraisal Determination: immunosuppressive therapy for kidney transplantation in adults

Thank you for your further letter of 8 February clarifying and reducing the issues listed under 2.1 of your appeal in response to my initial scrutiny letter. I can now let you have my final scrutiny decision. I consider your revised 2.1 to be a valid appeal point, specifically that it was unreasonable of the committee not to use a modelling approach based on clinical equivalence of prolonged-release and immediate-release tacrolimus and a different set of prices (as per point 1a2 of your original appeal letter).

I have already noted that I consider your other three points to be valid. There will be an oral hearing, details of which have been separately notified to you.

Yours sincerely

Andy McKeon
Vice Chair
National Institute for Health and Care Excellence